Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate plus prednisone with or without exemestane versus exemestane in ER-positive metastatic breast cancer after aromatase inhibitor progression
2011-000621-80Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Abiraterone acetate plus prednisone, Abiraterone acetate plus prednisone plus exemestane and Exemestane alone (3 arms). Primary endpoint: Progression-free survival. Started Jun 2011; status: completed.
02
Drugs
abirateroneprednisoneexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-000621-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000621-80.